Navigation Links
Cancer researchers receive NIH grant to advance brain tumor therapies from lab to clinical trials
Date:4/24/2008

Cancer researchers at Childrens Hospital of Pittsburgh of UPMC and the University of Pittsburgh Cancer Institute (UPCI) will further develop novel treatments for brain tumors through a new, five-year, $6.24 million grant to the University of Pittsburgh School of Medicine.

The grant from the National Institute of Neurological Disorders and Stroke (NINDS) will fund three projects aimed at developing cutting-edge treatment strategies for a type of brain tumor known as gliomas. The projects are led by principal investigator Ian Pollack, MD, chief of the Division of Pediatric Neurosurgery at Childrens Hospital and director of the UPCI Brain Tumor Program. This is the second five-year grant the Brain Tumor Program project has received from the NINDS.

In the laboratory over the last five years, our researchers have developed three unique and promising approaches to treating gliomas, which are the most common form of brain tumors, Dr. Pollack said. Over the next five years, our goal is to take these approaches from the laboratory to clinical trial and begin to have a direct impact on patients diagnosed with brain tumors.

The three projects and their respective investigators are:

  • Molecularly targeted therapies that interrupt the signaling pathways in the brain that drive tumor growth Dr. Pollack, also the Walter Dandy Professor of Neurosurgery at the University of Pittsburgh School of Medicine

  • Immunotherapy using segments of proteins that are overexpressed by brain tumors to vaccinate patients against tumor growth Hideho Okada, MD, PhD, associate professor in the departments of Neurological Surgery and Surgery at the University of Pittsburgh School of Medicine

  • Viral vectors (a modified herpes virus) to kill tumor cells while leaving other cells intact Joseph C. Glorioso III, PhD, chair of the Department of Microbiology and Molecular Genetics at the University of Pittsburgh School of Medicine; and Paola Grandi, PhD, an assistant professor in the departments of Neurological Surgery and Microbiology and Molecular Genetics at the University of Pittsburgh School of Medicine

Every year about 19,000 children and adults are diagnosed with primary brain tumors, according to the National Cancer Institute. Malignant gliomas are the most common, accounting for more than half and including astrocytomas, oligodendrogliomas and glioblastoma multiforme.

Current conventional therapies for malignant brain tumors, including surgery, radiation and chemotherapy, are often unsatisfactory for controlling these tumors, and the vast majority recur, Dr. Pollack said. We believe the projects here in Pittsburgh hold promise in improving the treatment of these challenging tumors.


'/>"/>

Contact: Marc Lukasiak
marc.lukasiak@chp.edu
412-692-7919
Children's Hospital of Pittsburgh
Source:Eurekalert

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... San Diego, CA (PRWEB) , ... March 28, 2017 , ... ... and turtlenecks from the daily wardrobe. However, for those self-conscious about a double chin, ... believe they have the ideal solution. , “For most people, a double chin ...
(Date:3/28/2017)... ... March 28, 2017 , ... Neurotechnology , ... biometric time and attendance tracking products: the new NCheck Cloud Bio Attendance cloud-based ... Attendance uses biometric face recognition to enable users to check in and out ...
(Date:3/28/2017)... ... March 28, 2017 , ... Columbus OH. Dr. Justin ... one of few medical professionals in the country to sit on the 2017 National ... Aesthetics, in just 2 years Dr. Harper helped propel the clinic from a small ...
(Date:3/28/2017)... Atlantic City, NJ (PRWEB) , ... March 28, ... ... annual American Camp Association’s Tri-State Camp Conference in Atlantic City March 13-16, was ... partners, and their team of professional staff discussed strategies for preventing outbreaks among ...
(Date:3/28/2017)... St. Louis, MO (PRWEB) , ... March 28, ... ... high levels of job satisfaction in their profession as their value increases in ... a company that provides resources such as job boards, career fairs, and candidate ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... United Kingdom and  BOSTON , March 28, ... Linguamatics today announced a partnership with ... The agreement allows pharmaceutical companies to extract key ... I2E text mining technology. The ... of the top 20 global pharmaceutical companies. The ...
(Date:3/28/2017)... , March 28, 2017  AcelRx Pharmaceuticals, Inc. ... the development and commercialization of innovative therapies for ... the European Medicines Agency (EMA) has notified the ... mcg) Marketing Authorisation Application (MAA) has passed validation, ... is underway. The MAA for ARX-04 (known as ...
(Date:3/28/2017)... 28, 2017 The global ... 8.0 billion by 2025, according to a new study ... infectious diseases and cancer is expected to upsurge the ... over the coming years. In addition, higher number of ... allogenic stem cell therapy, due to adverse effects caused ...
Breaking Medicine Technology: